Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Jinxin Fertility Group Placement - Weak Track Record And Recent Deals Have Performed Poorly

ECM Weekly (8th Jan 2022) - Sinohytec, Beauty Farm, Sula, Kfin, Bionote, Meidong, CIFI, Jinxin Fert

2022 High Conviction: Tail Winds for Jinxin Fertility

Jinxin Fertility: Accretive but Slightly Controversial Acquisition of Jinxin WCH

Jinxin Fertility 1H2021: A Clear Picture of the Long Term Potential

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Bottom-Up

Jinxin Fertility Group  / Equity Bottom-Up

<ul>
<li>Jinxin announced in recent days that it further increases stake in Shenzhen Hospital, Jiuzhou Hospital and Hewanjia Hospital.</li>
<li>In this note, we analyze the impact on the company. We think the acquisition is sensible when the market sentiment is weak. </li>
<li>We also summarize recent industry development and the company's FY2021 results. We are turning relatively more bearish.</li>
</ul>


Jinxin announced in recent days that it further increases stake in Shenzhen Hospital, Jiuzhou Hospital and Hewanjia Hospital.
In this note, we analyze the impact on the company. We think the acquisition is sensible when the market sentiment is weak. 
We also summarize recent industry development and the company's FY2021 results. We are turning relatively more bearish.


Jinxin Fertility: Shenzhen and Yunnan Acquisitions